Description
6-Bromoimidazo[1,2-A]pyrimidine-3-carboxylic acid (CAS No. 944903-05-3) is a high-purity heterocyclic compound with the molecular formula C7H4BrN3O2. This brominated imidazopyrimidine derivative is a valuable building block in organic synthesis and pharmaceutical research, offering versatile reactivity for the development of novel bioactive molecules. Its carboxylic acid functionality enables further derivatization, making it ideal for coupling reactions, metal-catalyzed transformations, and the synthesis of targeted drug candidates. The compound is supplied as a fine powder with ≥95% purity (HPLC), ensuring consistency for research applications. Store in a cool, dry place under inert conditions to maintain stability.
Properties
- CAS Number: 944903-05-3
- Complexity: 226
- IUPAC Name: 6-bromoimidazo[1,2-a]pyrimidine-3-carboxylic acid
- InChI: InChI=1S/C7H4BrN3O2/c8-4-1-9-7-10-2-5(6(12)13)11(7)3-4/h1-3H,(H,12,13)
- InChI Key: DIOGTIVUKTZYTE-UHFFFAOYSA-N
- Exact Mass: 240.94869
- Molecular Formula: C7H4BrN3O2
- Molecular Weight: 242.03
- SMILES: C1=C(N2C=C(C=NC2=N1)Br)C(=O)O
- Topological: 67.5
- Monoisotopic Mass: 240.94869
- Synonyms: 6-BROMOIMIDAZO[1,2-A]PYRIMIDINE-3-CARBOXYLIC ACID, 944903-05-3, MFCD09994670, SCHEMBL23534224, DTXSID80737408, SC4337, AKOS023399666, AB55755, AS-54668, DB-369220, CS-0094352, 6-BROMOIMIDAZO[1,2-A]PYRIMIDINE-3-CARBOXYLICACID
Application
6-Bromoimidazo[1,2-A]pyrimidine-3-carboxylic acid serves as a key intermediate in medicinal chemistry for the synthesis of kinase inhibitors and antiviral agents. Its imidazopyrimidine core is frequently employed in the development of small-molecule therapeutics targeting inflammatory and oncological pathways. Researchers utilize this compound to explore structure-activity relationships (SAR) in drug discovery programs.
If you are interested or have any questions, please contact us at support@atomfair.com
Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.


Reviews
There are no reviews yet.